Best Researcher Award

Yury Kustov is a researcher affiliated with the Peoples’ Friendship University of Russia whose scholarly work focuses on medicine, pharmacovigilance, drug safety, pulmonary fibrosis, and clinical pharmacology. His recent publications examine adverse drug reactions, pediatric pharmacotherapy, pulmonary complications, and systematic reviews related to pharmacokinetics and post-COVID-19 outcomes. Through contributions indexed in Scopus, Kustov has participated in interdisciplinary investigations concerning patient safety and evidence-based medical analysis.[1] His profile reflects active engagement in healthcare-related research areas associated with pharmacological monitoring and clinical risk assessment.[2]

Abstract

The academic contributions of Yury Kustov are associated with contemporary clinical medicine and pharmacovigilance research. His published studies explore adverse drug reactions, pulmonary fibrosis, antibiotic safety, and pediatric therapeutic outcomes. Several investigations emphasize spontaneous report database analysis and systematic reviews in order to improve healthcare monitoring and pharmacological safety standards.[3] These contributions support broader scientific discussions regarding medication-related complications and patient-centered clinical evaluation.

Keywords

Pharmacovigilance, Clinical Pharmacology, Pulmonary Fibrosis, Pediatric Medicine, Drug Safety, Post-COVID Research, Pharmacokinetics, Medicine and Health Sciences.

Introduction

The advancement of modern healthcare increasingly depends on pharmacological safety assessment and evidence-based therapeutic monitoring. Researchers involved in pharmacovigilance contribute to the identification of adverse reactions and clinical complications linked to pharmaceutical interventions. Yury Kustov has participated in this research landscape through studies addressing antibacterial drug reactions, pulmonary fibrosis, and pediatric medicine.[4] His publications demonstrate engagement with healthcare datasets and clinical literature reviews that contribute to scientific understanding of treatment-related risks.

Research Profile

Kustov’s academic profile includes journal articles and conference publications indexed through Scopus and related scholarly databases. His research areas include pharmacokinetics in chronic heart failure, pulmonary fibrosis associated with pharmacotherapy, and pediatric antibacterial drug safety. The researcher has also examined Stevens–Johnson syndrome and toxic epidermal necrolysis using spontaneous reporting systems.[5] These studies align with medical efforts to improve treatment evaluation and patient safety methodologies.

Research Contributions

• Analysis of fluoroquinolone safety in pediatric populations through pharmacovigilance database studies.
• Systematic review research concerning pharmacokinetic alterations in chronic heart failure patients.
• Investigations into pulmonary fibrosis and post-COVID-19 pharmacotherapy outcomes.
• Evaluation of spontaneous adverse drug reaction reports linked to antibacterial medications.

Publications

• “Safety of fluoroquinolones in pediatric patients: Pharmacovigilance database analysis”
• “Pharmacokinetic Alterations in Patients with Chronic Heart Failure: A Systematic Review”
• “Drug-Induced Pulmonary Fibrosis: National Database Analysis”

Research Impact

The research contributions of Yury Kustov demonstrate relevance to healthcare monitoring, medication safety assessment, and evidence-based pharmacology. By utilizing systematic reviews and spontaneous report analyses, his studies contribute to discussions surrounding adverse drug reaction surveillance and therapeutic evaluation. Such research supports clinicians, pharmacologists, and healthcare researchers seeking to understand treatment-related complications in vulnerable patient populations.

Award Suitability

Yury Kustov’s publication record and involvement in pharmacovigilance-related medical studies align with the objectives of the International Forensic Scientist Awards. His focus on drug safety analysis, pulmonary complications, and healthcare risk assessment reflects scholarly engagement with medically significant challenges. The integration of database-driven clinical analysis and systematic review methodologies further demonstrates research activity associated with modern healthcare science and patient protection initiatives.

Conclusion

Yury Kustov has contributed to medicine and health sciences through publications examining pharmacovigilance, pulmonary fibrosis, clinical pharmacology, and pediatric drug safety. His academic profile reflects ongoing participation in evidence-based medical research and healthcare monitoring studies. Through indexed scholarly outputs and DOI-linked publications, his work contributes to the broader scientific understanding of pharmaceutical safety and patient-centered clinical investigation.

External Links

• ORCID Profile
• Scopus Author Profile
• Award Website

References

1. Elsevier. (n.d.). Scopus author details: Yury Kustov, Author ID 58987836800. Scopus.
   https://www.scopus.com/authid/detail.uri?authorId=58987836800
2. ORCID. (n.d.). Yury Kustov ORCID profile.
   https://orcid.org/0009-0002-4859-4322
3. Kustov, Y. (2026). Safety of fluoroquinolones in pediatric patients: Pharmacovigilance database analysis.
   https://doi.org/10.1177/09246479251398995
4. Kustov, Y. (2025). Pharmacokinetic Alterations in Patients with Chronic Heart Failure: A Systematic Review.
   https://doi.org/10.3390/ijms26199495
5. Kustov, Y. (2024). Drug-Induced Pulmonary Fibrosis: National Database Analysis.
   https://doi.org/10.3390/biomedicines12122650